Gene therapy stocks
Heavily traded in Gene therapy
Turnover over $10M/day11 of about 40 companies in this theme turn over more than $10M in a typical session. Largest market value first. Data as of Sep 15, 2026.
| Company | Turnover | 1Y return | Next report |
|---|---|---|---|
| KRYSKrystal Biotech, Inc. | $98.58M | +118.37% | Nov 2, 2026 |
| QUREuniQure N.V. | $51.18M | +202.86% | Nov 9, 2026 |
| BEAMBeam Therapeutics Inc. | $44.06M | +13.35% | Nov 3, 2026 |
| PGENPrecigen, Inc. | $30.24M | +90.81% | Nov 12, 2026 |
| SRPTSarepta Therapeutics, Inc. | $60.99M | +19.75% | Nov 4, 2026 |
| NTLAIntellia Therapeutics, Inc. | $41.12M | +2.59% | Nov 5, 2026 |
| TSHATaysha Gene Therapies, Inc. | $12.07M | +65.89% | Nov 4, 2026 |
| RGNXREGENXBIO Inc. | $11.74M | −4.40% | Nov 5, 2026 |
Turnover is the median value traded in one session, measured over the past 50 sessions. It describes trading activity in a stock and nothing about the company behind it.
Table
41 companies, largest market value first.
Data as of Sep 15, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| KRYS | Krystal Biotech, Inc. | $10.06B | Large cap | +118.37% |
| QURE | uniQure N.V. | $3.12B | Mid cap | +202.86% |
| BEAM | Beam Therapeutics Inc. | $2.49B | Mid cap | +13.35% |
| PGEN | Precigen, Inc. | $2.44B | Mid cap | +90.81% |
| SRPT | Sarepta Therapeutics, Inc. | $2.21B | Mid cap | +19.75% |
| NTLA | Intellia Therapeutics, Inc. | $1.66B | Small cap | +2.59% |
| TSHA | Taysha Gene Therapies, Inc. | $1.63B | Small cap | +65.89% |
| MGTX | MeiraGTx Holdings plc | $1.24B | Small cap | +75.72% |
| SLDB | Solid Biosciences Inc. | $937.15M | Small cap | +59.20% |
| FDMT | 4D Molecular Therapeutics, Inc. | $760.16M | Small cap | +102.35% |
| NGNE | Neurogene Inc. | $704.60M | Small cap | +101.78% |
| C2RS34.SA | CRISPR Therapeutics AG | $639.02M | Small cap | −20.99% |
| PRME | Prime Medicine, Inc. | $576.78M | Small cap | −20.70% |
| RGNX | REGENXBIO Inc. | $573.65M | Small cap | −4.40% |
| IRD | Opus Genetics, Inc. | $496.68M | Small cap | +335.77% |
| EDIT | Editas Medicine, Inc. | $420.81M | Small cap | +2.62% |
| BNTC | Benitec Biopharma Inc. | $415.00M | Small cap | −11.82% |
| CRNA.OL | Circio Holding ASA | $393.84M | Small cap | +1991.80% |
| RCKT | Rocket Pharmaceuticals, Inc. | $376.53M | Small cap | +6.52% |
| OCGN | Ocugen, Inc. | $359.46M | Small cap | −11.67% |
| LXEO | Lexeo Therapeutics, Inc. | $345.41M | Small cap | −21.75% |
| ABEO | Abeona Therapeutics Inc. | $310.51M | Small cap | −5.24% |
| KRRO | Korro Bio, Inc. | $204.39M | Small cap | −55.73% |
| VYGR | Voyager Therapeutics, Inc. | $196.56M | Small cap | −24.23% |
| DTIL | Precision BioSciences, Inc. | $189.35M | Small cap | +52.44% |
| TNYA | Tenaya Therapeutics, Inc. | $155.37M | Small cap | −42.25% |
| ALSEN.PA | Sensorion SA | $129.41M | Small cap | −23.75% |
| ENGN | enGene Therapeutics Inc. | $125.32M | Small cap | −68.68% |
| 4BB.L | 4basebio PLC | $100.30M | Small cap | −42.86% |
| SGMO | Sangamo Therapeutics, Inc. | $91.14M | Micro cap | −56.86% |
| 4563.T | AnGes, Inc. | $90.18M | Micro cap | −60.23% |
| MGX | Metagenomi Therapeutics, Inc. | $44.95M | Micro cap | −34.62% |
| GNTA | Genenta Science S.p.A. | $40.09M | Micro cap | −72.39% |
| SIGHT.PA | GenSight Biologics S.A. | $32.05M | Micro cap | −25.73% |
| 0R1D.L | Sangamo Therapeutics, Inc. | $31.87M | Micro cap | −72.72% |
| 4883.T | Modalis Therapeutics Corporation | $22.25M | Micro cap | −58.02% |
| GENF.L | Genflow Biosciences plc | $16.82M | Micro cap | +82.43% |
| PASG | Passage Bio, Inc. | $15.64M | Micro cap | −30.07% |
| GNPX | Genprex, Inc. | $2.83M | Micro cap | −74.91% |
| 0VRQ.L | CRISPR Therapeutics AG | — | — | −12.46% |
| CRNAO.OL | Circio Holding ASA | — | — | +1248.84% |
Covers ~23,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Price and the 52-week distance are in the currency the stock trades in; only market values are converted.
We cover 41 companies grouped under the Gene therapy theme. The median market value in the group is $359.46M. Across the group, the median move over the past trading day is +0.18%. 44% of the 39 with a 200-day average trade above it. Price change over the past year runs from −60.2% to +118.4% across the middle 80 percent of the group, with a median of −11.7%.